An AI-Designed Lung Disease Drug Just Reached Phase III, One of Only a Handful to Get This Far
Insilico Medicine has advanced rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, into a Phase III trial of 320 patients, making it one of only a handful of AI-discovered therapeutics to reach late-stage testing.